☆ 4.7 Letter

Tumor response to sunitinib malate observed in clear-cell sarcoma

ANNALS OF ONCOLOGY (2010)

Journal

ANNALS OF ONCOLOGY

Volume 21, Issue 5, Pages 1130-1131

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdp611

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma

Xiaoyi Du, Zhipeng Zhao, Xin Zhao, Hexi Wang, Li Jiang, Wei Tang

Summary: In this study, we analyzed the subtypes of ccRCC mediated by 8 TSGs contained in the 3p21.3 gene cluster and their effects on TME cell infiltration. A risk score model was established to predict prognosis and drug sensitivity. The hub gene NPRL2 was found to promote sunitinib sensitivity in ccRCC cells.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Add to Collection

Article Multidisciplinary Sciences

miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma

Sang Eun Park, Wonju Kim, Ji-Ye Hong, Dayeon Kang, Seulki Park, Jungyo Suh, Dalsan You, Yun-Yong Park, Nayoung Suh, Jung Jin Hwang, Choung-Soo Kim

Summary: This study identified miR-96-5p as a key regulator in sunitinib resistance in CCRCC by direct suppression of PTEN, leading to poor prognosis in patients with high miR-96-5p and low PTEN levels.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Biochemical Research Methods

Engineering of a Biosensor in Response to Malate in Bacillus licheniformis

Yupeng Zhang, Youran Li, Fengxu Xiao, Hanrong Wang, Liang Zhang, Zhongyang Ding, Sha Xu, Zhenghua Gu, Guiyang Shi

Summary: A genetically encoded biosensor responding to malate was constructed in Bacillus licheniformis, enabling direct and precise detection of malate in microbial metabolism. The biosensor can respond to malate concentrations ranging from 5 to 15 g/L, showing a linear correlation between eGFP fluorescence and malate concentration. This engineering biosensor enriches the toolbox of synthetic biology for pathway engineering in malate production in microorganisms.

ACS SYNTHETIC BIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report

Junyue Tao, Hao Yang, Zongyao Hao, Chaozhao Liang, Yingying Du, Chao Zhang, Yu Yin, Jun Zhou

Summary: This case report describes the use of anlotinib combined with chemotherapy in treating recurrent clear cell sarcoma, which has shown promising results and may be an effective treatment option.

MEDICINE (2022)

Add to Collection

Article Oncology

Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 CREATE Trial

Che-Jui Lee, Elodie Modave, Bram Boeckx, Silvia Stacchiotti, Piotr Rutkowski, Jean-Yves Blay, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak, Patrick Schoffski

Summary: The study found that limited responses to the MET inhibitor crizotinib in CCSA patients may be due to infrequent activation of the MET pathway. Molecular analysis revealed potential predictive or prognostic molecular alterations in CCSA patients, providing new insights for future therapeutic approaches.

CANCERS (2021)

Add to Collection

Article Oncology

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients

Angelika M. Starzer, Anna S. Berghoff, Rainer Hamacher, Erwin Tomasich, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Wolfgang Lamm, Iris M. Noebauer-Huhmann, Julia Furtner, Leonhard Muellauer, Gabriele Amann, Sebastian Bauer, Hans-Ulrich Schildhaus, Matthias Preusser, Gerwin Heller, Thomas Brodowicz

Summary: The study demonstrates that tumor DNA methylation profiles may serve as a predictive marker for response to anti-PD-1 ICI therapy in patients with sarcoma. Analysis of methylation data helps to identify differences between responders and non-responders, aiding in predicting treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma

Licheng Wang, Yaru Zhu, Zhen Ren, Wenhuizi Sun, Zhijing Wang, Tong Zi, Haopeng Li, Yan Zhao, Xin Qin, Dacheng Gao, Libo Zhang, Ziyang He, Wei Le, Qiang Wu, Gang Wu

Summary: The study found that the ICD score is associated with prognosis in patients with kidney clear cell carcinoma (KIRC), with higher ICD scores indicating clinical benefits in immunotherapy. Therefore, the ICD score can serve as an accurate and valid predictor to assess the effect of immunotherapy.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

Evan Rosenbaum, Cristina R. Antonescu, Shaleigh Smith, Martina Bradic, Daniel Kashani, Allison L. Richards, Mark Donoghue, Ciara M. Kelly, Benjamin Nacev, Jason E. Chan, Ping Chi, Mark A. Dickson, Mary L. Keohan, Mrinal M. Gounder, Sujana Movva, Viswatej Avutu, Katherine Thornton, Ahmet Zehir, Anita S. Bowman, Samuel Singer, William Tap, Sandra D'Angelo

Summary: This study retrospectively evaluated the clinical and molecular characteristics of angiosarcoma patients treated with ICB therapy. The results showed that ICB therapy is effective in some angiosarcoma patients, particularly those with cutaneous angiosarcoma of the head and neck.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Differentiation between Clear Cell. Sarcoma of the Kidney and Wilms' Tumor with CT

Choeum Kang, Hyun Joo Shin, Haesung Yoon, Jung Woo Han, Chuhl Joo Lyu, Mi Jung Lee

Summary: This study reviewed CT scans of children with CCSK and Wilms' tumor between 2010 to 2019. It found that engorged perinephric vessels were more common in CCSK patients, and higher values of Tmax/muscle and Tmax/vein were observed in the CCSK group, which can serve as important indicators for diagnosing CCSK.

KOREAN JOURNAL OF RADIOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines

Christina Karner, Ines Anders, Djenana Vejzovic, Joanna Szkandera, Susanne Scheipl, Alexander J. A. Deutsch, Larissa Weiss, Klemens Vierlinger, Dagmar Kolb, Stefan Kuehberger, Ellen Heitzer, Hansjoerg Habisch, Fangrong Zhang, Tobias Madl, Birgit Reininger-Gutmann, Bernadette Liegl-Atzwanger, Beate Rinner

Summary: This study successfully established two clear cell sarcoma (CCS) cell lines from different patients, as well as healthy fibroblast cell lines from the same patient. By comparing these cell lines, the researchers found differences in morphology, genetic and epigenetic characteristics, reflecting the original tissue differences. This cell line model can be used to investigate new therapies, such as PRMT1 inhibitors, which have targeted anti-tumor effects on CCS cells but no effect on fibroblasts.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Pharmacology & Pharmacy

Endoplasmic Reticulum Stress-Related Signature Predicts Prognosis and Drug Response in Clear Cell Renal Cell Carcinoma

Yuke Zhang, Yancheng Song, Jiangwen Dai, Zhaoxiang Wang, Yuhao Zeng, Feng Chen, Peng Zhang

Summary: This study revealed the association between ER stress and the progression and prognosis of ccRCC through the analysis of ccRCC samples from the TCGA database. An ER stress-related prognostic risk model was constructed and a nomogram was proposed. Moreover, new therapeutic compounds were screened out.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor

Hailiang Zhang, Lin Bai, Xin-Qiang Wu, Xi Tian, Jinwen Feng, Xiaohui Wu, Guo-Hai Shi, Xiaoru Pei, Jiacheng Lyu, Guojian Yang, Yang Liu, Wenhao Xu, Aihetaimujiang Anwaier, Yu Zhu, Da-Long Cao, Fujiang Xu, Yue Wang, Hua-Lei Gan, Meng-Hong Sun, Jian-Yuan Zhao, Yuanyuan Qu, Dingwei Ye, Chen Ding

Summary: This study investigates the molecular basis of differential clinical outcomes with TKI therapy in ccRCC patients undergoing Sunitinib treatment. They find that mTOR signaling activation induced by chromosome 7q gain is associated with poor therapeutic outcomes, while enhanced glycolysis caused by the aristolochic acid signature and VHL mutation correlates with better prognosis. A multi-omics classifier is developed to detect responder and non-responder patients.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Adrenomedullin/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis

Xin Wang, Jiang-Hua Jia, Ming Zhang, Qing-Song Meng, Bo-Wen Yan, Zi-Yue Ma, Dong-Bin Wang

Summary: This study found that the upregulation of ADM enhanced the chemoresistance of sunitinib by inhibiting FDX1 expression through cuproptosis. Mechanistically, ADM activates the p38/MAPK signaling pathway to promote FOXO3 phosphorylation and its entry into the nucleus, resulting in the inhibition of FDX1 transcription and cell cuproptosis, ultimately promoting chemoresistance in ccRCC.

FASEB JOURNAL (2023)

Add to Collection

Article Oncology

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance

Chenchen Feng, Yuqing Li, Kunping Li, Yinfeng Lyu, Wenhui Zhu, Haowen Jiang, Hui Wen

Summary: PFKFB4 was found to be significantly overexpressed in tumors compared to normal kidney, associated with advanced tumor grade, stage and poor prognosis. PFKFB4 overexpression impaired cell proliferation, migration, and wound healing. Targeting PFKFB4 showed promise in overcoming resistance to Sunitinib.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Medicine, Research & Experimental

The clear cell sarcoma functional genomic landscape

Emanuele Panza, Benjamin B. Ozenberger, Krystal M. Straessler, Jared J. Barrott, Li Li, Yanliang Wang, Mingchao Xie, Anne Boulet, Simon W. A. Titen, Clinton C. Mason, Alexander J. Lazar, Li Ding, Mario R. Capecchi, Kevin B. Jones

Summary: Clear cell sarcoma is a deadly malignancy affecting adolescents and young adults, characterized by frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations are shared with other EWSR1-rearranged tumors.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Oncology

Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases

Andrea Ferrari, Stefano Chiaravalli, Luca Bergamaschi, Olga Nigro, Virginia Livellara, Giovanna Sironi, Patrizia Gasparini, Sandro Pasquali, Nadia Zaffaroni, Silvia Stacchiotti, Carlo Morosi, Maura Massimino, Michela Casanova

Summary: Combining trabectedin and irinotecan may be an effective chemotherapy for desmoplastic small round cell tumors (DSRCT).

JOURNAL OF CHEMOTHERAPY (2023)

Add to Collection

Article Oncology

CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study

Anna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, Jean-Michelle Coindre, Antoine Italiano, Cleofe Romagnosa, Silvia Bague, Angelo Paolo Dei Tos, Luca Braglia, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Antonella Brunello, Jean-Yves Blay, Robert Diaz Beveridge, Iwona Lugowska, Tom Lesluyes, Roberta Maestro, Franco Domenico Merlo, Paolo Giovanni Casali, Alessandro Gronchi

Summary: The results of this study suggest that CINSARC has weak prognostic power in high-risk, localized soft tissue sarcoma patients.

CANCER MEDICINE (2023)

Add to Collection

Article Orthopedics

Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN

John H. Healey, William D. Tap, Heather L. Gelhorn, Xin Ye, Rebecca M. Speck, Emanuela Palmerini, Silvia Stacchiotti, Jayesh Desai, Andrew J. Wagner, Thierry Alcindor, Kristen Ganjoo, Javier Martin-Broto, Qiang Wang, Dale Shuster, Hans Gelderblom, Michiel van de Sande

Summary: Pexidartinib provides modest pain reduction, slightly larger than the minimum clinically important difference (MCID), in patients with tenosynovial giant cell tumors (TGCT) not amenable to improvement with surgery，although it is not enough to justify its routine use for pain relief.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2023)

Add to Collection

Article Oncology

Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry

Bruno Vincenzi, Andrea Napolitano, Alessandro Comandone, Roberta Sanfilippo, Simone Celant, Pier P. Olimpieri, Susanna Di Segni, Pierluigi Russo, Paolo G. Casali

Summary: This study analyzed the use of trabectedin in Italian patients with soft-tissue sarcomas and found that trabectedin is effective in treating leiomyosarcoma and liposarcoma patients.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators

Philip Heesen, Gabriela Studer, Beata Bode, Hubi Windegger, Benjamin Staeheli, Paul Aliu, Javier Martin-Broto, Alessandro Gronchi, Jean-Yves Blay, Axel Le Cesne, Bruno Fuchs

Summary: This article presents a comprehensive analysis of quality indicators for sarcoma care and introduces a novel interoperable digital platform that gathers information from physicians and patients consecutively and instantly. The platform provides evidence of care quality by analyzing real-time world information, enabling predictive modeling and value-based health care. The lack of global data harmonization and quality standards, as well as discipline, institution, and network fragmentation, hinder the progress in sarcoma care. To improve quality, a common definition of quality indicators and the assessment of longitudinal real-time data are required. An international advisory board defined six categories of quality indicators, which were programmed into the digital platform for analysis and visualization. Standardized quality indicators and their real-time assessment are critical to improving the quality of sarcoma care.

CANCERS (2023)

Add to Collection

Editorial Material Oncology

ASO Author Reflections: Organ Infiltration in Retroperitoneal Liposarcomas: A Novel Prognostic Factor?

Luca Improta, Sandro Pasquali, Sergio Valeri, Alessandro Gronchi

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Letter Oncology

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)

Jacob Lambdin, Carrie Ryan, Stephanie Gregory, Kenneth Cardona, Jonathan M. Hernandez, Winan J. van Houdt, Alessandro Gronchi

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Organ Infiltration and Patient Risk After Multivisceral Surgery for Primary Retroperitoneal Liposarcomas

Luca Improta, Sandro Pasquali, Sara Iadecola, Marta Barisella, Marco Fiore, Stefano Radaelli, Chiara Colombo, Rossana Alloni, Dario Callegaro, Sergio Valeri, Rosalba Miceli, Alessandro Gronchi

Summary: This study investigated the impact of histological organ involvement (HOI) on the prognosis of primary retroperitoneal liposarcoma. Initial and advanced HOIs were frequently detected in both well-differentiated and de-differentiated liposarcomas, suggesting the need for multivisceral resection. HOI stratifies the risk of patients with primary retroperitoneal liposarcoma.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

NIRO or No-go? Positioning a Novel Systemic Treatment Option for Desmoid Tumours

Herbert H. Loong, Abha Gupta, Alessandro Gronchi

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Six Surgical Stages in the Resection of Primary Right Retroperitoneal Liposarcoma: A Standardized Comprehensive Approach

Stefano Radaelli, Marco Baia, Ashley Drohan, Carlo Morosi, Claudia Sangalli, Chiara Colombo, Dario Callegaro, Marco Fiore, Alessandro Gronchi

Summary: This study presents a reproducible and standardized six-stage approach for the surgical treatment of primary retroperitoneal liposarcoma. The patient underwent en bloc resection of the retroperitoneal mass along with the kidney, adrenal gland, colon, psoas muscle, and diaphragm. Resection of retroperitoneal sarcoma is a complex procedure that requires a broad range of surgical expertise.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

ASO Visual Abstract: Organ Infiltration and Patient Risk After Multivisceral Surgery for Primary Retroperitoneal Liposarcomas

Luca Improta, Sandro Pasquali, Sara Iadecola, Marta Barisella, Marco Fiore, Stefano Radaelli, Chiara Colombo, Rossana Alloni, Dario Callegaro, Sergio Valeri, Rosalba Miceli, Alessandro Gronchi

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

Robbe Saesen, Mieke Van Hemelrijck, Jan Bogaerts, Christopher M. Booth, Jan J. Cornelissen, Andre Dekker, Elizabeth A. Eisenhauer, Andre Freitas, Alessandro Gronchi, Miguel A. Hernan, Frank Hulstaert, Piet Ost, Petr Szturz, Helena M. Verkooijen, Michael Weller, Roger Wilson, Denis Lacombe, Winette T. van der Graaf

Summary: The precision medicine paradigm in oncology has sparked interest in integrating real-world data (RWD) into cancer research. RWD studies tend to focus on collecting and analyzing observational data, but randomized controlled trials (RCTs) have the potential to generate strong evidence. The European Organisation for Research and Treatment of Cancer (EORTC) prioritizes pragmatic trials and trials-within-cohorts to generate robust RWD, but will consider observational research based on the target trial principle if random allocation is not feasible. New EORTC-sponsored trials may also include concurrent prospective cohorts.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis

Claudia Giani, Stefano Radaelli, Rosalba Miceli, Lorenza Gandola, Claudia Sangalli, Anna Maria Frezza, Salvatore Provenzano, Sandro Pasquali, Rossella Bertulli, Marco Fiore, Dario Callegaro, Michela Casanova, Stefano Chiaravalli, Paola Collini, Gian Paolo Dagrada, Carlo Morosi, Nadia Zaffaroni, Paolo G. Casali, Andrea Ferrari, Alessandro Gronchi, Silvia Stacchiotti

Summary: A retrospective study on primary DSRCT was conducted to characterize long-term survivors (LTS). It was found that 13% of patients achieved cure, who had no liver or extra-abdominal metastasis at diagnosis, received complete surgery, and possibly underwent whole abdomino-pelvic radiotherapy (WAP-RT) and maintenance chemotherapy (MC).

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study

Silvia Stacchiotti, Giacomo Giulio Baldi, Anna Maria Frezza, Carlo Morosi, Francesca Gabriella Greco, Paola Collini, Marta Barisella, Gian Paolo Dagrada, Nadia Zaffaroni, Sandro Pasquali, Alessandro Gronchi, Paul Huang, Matilde Ingrosso, Gabriele Tine, Rosalba Miceli, Paolo Giovanni Casali

Summary: This study investigated the activity of regorafenib in advanced solitary fibrous tumour (SFT). The results showed that regorafenib demonstrated activity in SFT, with 30% of patients being progression-free at one year. However, the overall response rate (ORR) and median progression-free survival (mPFS) were lower compared to other antiangiogenic agents.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.